Clinical Trial Technology Editorial

  1. When AI Agents Start Researching Trials On Behalf Of Patients, What Happens? 5/13/2026

    Right now, patients are using AI agents to find clinical trials. But soon enough, these AI tools will be doing it on their own and feeding patients the results. Recruitment expert Ross Jackson discusses this shift and what it will mean for sponsors.

  2. Safe And Scalable AI Deployment For Clinical Trials 5/11/2026

    When life sciences organizations lack a structured, evidence-based methodology for scaling AI tools safely and effectively, they put clinical development at risk. Partha Anbil and Partha Khot team up to share a practical approach to its implementation.

  3. Small Biotech Survival: Navigating Risk And Capital Scarcity With AI 5/8/2026

    Maxine Opperman discusses the challenge and the necessity of small biotech's using AI, citing its pros, cons, and strategies for use.

  4. Human-In-The-Loop In AI Validation And Control: From Principle To Practice 4/28/2026

    Explores how human-in-the-loop oversight can move from principle to practice. with a risk-based framework for determining when HITL is required, how the human role should be defined, and what organizational factors influence its effectiveness.

  5. Reimagining Data Governance For The AI Era 4/24/2026

    Understand the persistent governance challenges that undermine AI initiatives and walk away with a robust blueprint for building a resilient, scalable, and ethically sound framework.

  6. Navigating Elsa's AI Transition: Practical Guidance To Safeguard Confidential Information (Part 3) 4/22/2026

    With FDA's Claude-to-Gemini transition underway within Elsa, Kimberly Chew, Esq., and Michael Yang, Esq., offer advice for proactive risk management to safeguard trade secrets and regulatory outcomes in part three of this series on Elsa's AI transition.

  7. AI Amplifies Capabilities But Also Risks: Learn The Legal Consequences Of AI In Clinical Research 4/16/2026

    Companies that successfully use AI are those that understand technology magnifies accountability. Anyone that fails to internalize that lesson could find themselves defending the very systems they relied on to bring those products to market.

  8. Is It Time To Replace RECIST — Or Just Add AI? 4/16/2026

    Immunocore Chief Regulatory and Quality Officer Mark Moyer explains why new tools, including AI-based approaches, may better capture cancer treatment response than existing measures, such as ir-RECIST.

  9. RBQM And Centralized Monitoring Need Action 4/10/2026

    After COVID forced sponsors to move faster than ever, many are now confronting a harder challenge: ownership. Marci Thear explains why RBQM and centralized monitoring only work when sponsors move beyond reviewing outputs and start acting on the signals.

  10. RWE Is Ready — Decision Making For Pharmaceuticals Isn't 4/1/2026

    Gorana Capkun of Merck, KGaA, Darmstadt, Germany discusses the growing role of real-world evidence in clinical trials, highlighting a gap between regulatory momentum and pharma adoption— and the challenge of turning data into better decisions.